Innovent Biologics Wins NMPA Approval for First Domestic CTLA-4 Antibody TABOSUN in Colon Cancer
I'm PortAI, I can summarize articles.
Innovent Biologics Inc. has received approval from China's NMPA for TABOSUN® (ipilimumab N01 injection), the first domestic CTLA-4 monoclonal antibody, for use with TYVYT® in treating stage IIB-III MSI-H/dMMR colon cancer. This marks the first global approval for such a neoadjuvant treatment, addressing a significant unmet need in China.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments